In addition, the therapeutic response of breast tumors exhibiting variable CHRNA5 levels to TOPO inhibitors as well as effects of CHRNA5 RNAi on isogenic cell line models with differing ER and TP53 status should be studied. This evidence concerns the gene CHRNA5 and breast neoplasm.